BTAI BioXcel Therapeutics, Inc.

Nasdaq bioxceltherapeutics.com


$ 2.28 $ -0.04 (-1.73 %)    

Tuesday, 18-Feb-2025 17:28:21 EST
QQQ na $ 1.22 (0.23 %)
DIA na $ 0.13 (0.03 %)
SPY na $ 1.79 (0.29 %)
TLT na $ -1.05 (-1.18 %)
GLD na $ 4.41 (1.66 %)
$ 2.27
$ 2.34
-- x --
-- x --
$ 2.21 - $ 2.36
$ 2.16 - $ 60.48
116,280
na
6.17M
$ 1.50
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2024 09-30-2024 10-Q
2 08-06-2024 06-30-2024 10-Q
3 05-09-2024 03-31-2024 10-Q
4 03-22-2024 12-31-2023 10-K
5 11-14-2023 09-30-2023 10-Q
6 08-14-2023 06-30-2023 10-Q
7 05-09-2023 03-31-2023 10-Q
8 03-16-2023 12-31-2022 10-K
9 11-14-2022 09-30-2022 10-Q
10 08-11-2022 06-30-2022 10-Q
11 05-09-2022 03-31-2022 10-Q
12 03-11-2022 12-31-2021 10-K
13 11-10-2021 09-30-2021 10-Q
14 08-10-2021 06-30-2021 10-Q
15 05-10-2021 03-31-2021 10-Q
16 03-12-2021 12-31-2020 10-K
17 11-12-2020 09-30-2020 10-Q
18 08-14-2020 06-30-2020 10-Q
19 05-12-2020 03-31-2020 10-Q
20 03-09-2020 12-31-2019 10-K
21 11-14-2019 09-30-2019 10-Q
22 08-06-2019 06-30-2019 10-Q
23 05-07-2019 03-31-2019 10-Q
24 03-12-2019 12-31-2018 10-K
25 11-09-2018 09-30-2018 10-Q
26 08-08-2018 06-30-2018 10-Q
27 05-14-2018 03-31-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bioxcel-therapeutics-updates-on-progress-of-its-late-stage-clinical-programs-for-lead-neuroscience-asset-bxcl501

The majority of trial sites have been opened and patient enrollment is progressing with the SERENITY At-Home trial of BXCL501 f...

 hc-wainwright--co-maintains-buy-on-bioxcel-therapeutics-lowers-price-target-to-3

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the pr...

 bioxcel-therapeutics-files-for-resale-of-up-to-51m-shares-by-the-selling-stockholders

- SEC Filing

 b-of-a-securities-downgrades-bioxcel-therapeutics-to-underperform-lowers-price-target-to-025

B of A Securities analyst Geoff Meacham downgrades BioXcel Therapeutics (NASDAQ:BTAI) from Buy to Underperform and lowers th...

 canaccord-genuity-maintains-buy-on-bioxcel-therapeutics-lowers-price-target-to-5

Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price targe...

 bioxcel-therapeutics-prices-7m-public-offering-of-56m-shares-and-warrants-at-048-per-unit-with-proceeds-supporting-neuroscience-and-immuno-oncology-development-efforts

Including Pre-Funded Warrants For Up To 9M Shares, 

 bioxcel-therapeutics-commences-public-offering-of-shares-of-its-common-stock-and-accompanying-warrants-no-terms-disclosed

The Company intends to use the net proceeds of this offering to fund the SERENITY At-Home trial, prepare for the initiation of ...

 bioxcel-therapeutics-q3-2024-gaap-eps-032-beats-060-estimate-sales-21400k-miss-131m-estimate

BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of ...

 bioxcel-therapeutics-announced-the-achievement-of-clinical-and-regulatory-progress-for-its-pivotal-phase-3-trials-of-bxcll501-for-the-acute-treatment-of-agitation-associated-with-bipolar-disorders-or-schizophrenia-serenity-at-home-and-agitation-associated-with-alzheimers-dementia-tranquility-in-care

SERENITY At-Home Pivotal Phase 3 trialDesigned to evaluate the safety of a 120 mcg dose of BXCL501 in the at-home setting for a...

 hc-wainwright--co-maintains-buy-on-bioxcel-therapeutics-lowers-price-target-to-5

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the pr...

 hc-wainwright--co-reiterates-buy-on-bioxcel-therapeutics-maintains-7-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $7...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION